Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Tafasitamab
DRUG: Acalabrutinib

Sponsor

International Extranodal Lymphoma Study Group (IELSG)